Background Epidemiological studies suggest that raised plasma concentrations of total homocysteine might be a risk factor for major vascular events. Whether lowering total homocysteine with B vitamins prevents major vascular events in patients with previous stroke or transient ischaemic attack is unknown. We aimed to assess whether the addition of once-daily supplements of B vitamins to usual medical care would lower total homocysteine and reduce the combined incidence of non-fatal stroke, non-fatal myocardial infarction, and death attributable to vascular causes in patients with recent stroke or transient ischaemic attack of the brain or eye.
Introduction
After an ischaemic stroke or transient ischaemic attack of the brain or eye, patients remain at increased risk of future stroke, myocardial infarction, or vascular death (major vascular events) despite use of medical and surgical therapies.
1 Cross-sectional and observational epidemiological studies suggest that raised plasma concentrations of total homocysteine are a common causal risk factor for major vascular events. [2] [3] [4] Furthermore, randomised trials show that total homocysteine can be lowered by supplementary treatment with B vitamins: 0·5-5·0 mg folic acid daily lowers total homo cysteine by 25% (95% CI 23-28%) and 0·02-1·00 mg vitamin B12 (mean 0·50 mg) daily lowers total homocysteine by 7% (3-10%). 5 However, whether lowering total homocysteine prevents major vascular events in patients with stroke and transient ischaemic attack is unknown. There have been no placebo-controlled trials of B vitamins in patients with stroke or transient ischaemic attack. The only previous randomised trial of treatment with B vitamins in patients with a history of stroke-the Vitamins Intervention for Stroke Prevention (VISP) trial 6 -compared high-dose B vitamins (25 mg pyridoxine, 0·4 mg cobalamin, and 2·5 mg folic acid) with low-dose B vitamins (200 μg pyridoxine, 6 μg cobalamin, and 20 μg folic acid) and was stopped because of futility after 3680 patients had been followed up for a mean of 20 months. There was no diff erence in the primary outcome of cerebral infarction between the groups (risk ratio [RR] 1·0, 95% CI 0·8-1·3), despite a mean reduction of total homocysteine of 2 μmol/L among patients assigned to high-dose B vitamins compared with those assigned to low-dose B vitamins. 6 However, in an effi cacy analysis of 2155 patients who were deemed most likely to benefi t from treatment with B vitamins (ie, excluding patients with low vitamin B12 concentrations who were unable to absorb oral vitamin B12 and patients with high vitamin B12 concentrations who were already taking a vitamin B12 supplement), there was a 21% (95% CI 0-37%) reduction in the combined outcome of ischaemic stroke, coronary disease, or death in patients assigned to high-dose B vitamins compared with those assigned to low-dose B vitamins. 7 Trials in other populations of patients have not shown a signifi cant benefi t of B vitamins compared with placebo in reducing major vascular events. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] This absence of detectable benefi t has several possible explanations: there might have been too few outcome events to provide suffi cient statistical power for a modest but clinically important eff ect to be reliably identifi ed or excluded; the doses of B vitamins might have been too low; the duration of treatment with B vitamins might have been too short; results might have been aff ected by food concurrently being fortifi ed with folic acid; and, if total homocysteine is a marker and not a cause of vascular risk, lowering total homocysteine might have no eff ect on vascular risk.
The VITAmins TO Prevent Stroke (VITATOPS) trial aimed to test the hypothesis that the addition of oncedaily supplements of B vitamins to usual medical care would reduce the combined incidence of non-fatal stroke, non-fatal myocardial infarction, and death attributable to vascular causes among patients with recent stroke or transient ischaemic attack of the brain or eye.
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Methods
Patients
The rationale and design of the VITATOPS trial have been published previously. 23, 24 Briefl y, VITATOPS was a prospective, randomised, double-blind, placebocontrolled clinical trial involving 123 medical centres in 20 countries from four continents. VITATOPS was undertaken in accordance with the Declaration of Helsinki and the CONSORT guidelines. 25, 26 Patients were eligible for inclusion if they had had a stroke (ischaemic or haemorrhagic) or transient ischaemic attack (eye or brain), as defi ned by standard criteria, 27 within the past 7 months. Patients with haemorrhagic stroke were included because the underlying cause is frequently intracranial small vessel disease 27 and the prognosis can include ischaemic strokes and coronary events that might respond to B-vitamin therapy. 28, 29 We chose the cutoff of 7 months to allow for the inclusion of patients who had already been enrolled in an acute stroke treatment trial and who needed to complete the fi nal 6-month follow-up for that trial before they could be eligible to enrol in other trials, such as VITATOPS. Patients were excluded if they were taking folic acid, vitamin B6, vitamin B12, or a folate antagonist (eg, methotrexate); if they were pregnant or were women of childbearing potential; or if they had a limited life expectancy (eg, because of ill health).
The trial received ethics approval from national (India, New Zealand, and the UK) and local research ethics committees and all patients provided written informed consent before enrolment.
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Randomisation and masking
Patients were randomly assigned to receive either B vitamins (2 mg folic acid, 25 mg vitamin B6, and 0·5 mg vitamin B12) or matching placebo that had the same colour and coating. Random allocation was done by use of a central 24 h telephone service or an interactive website by use of random permuted blocks stratifi ed by hospital. Patients, clinicians, trial coordinators, and outcome investigators were masked to treatment allocation. The data monitoring and safety committee, who were unmasked to treatment allocation, reviewed the safety data every 6 months and reported to the steering committee.
Procedures
Demographic and clinical characteristics of the participants were recorded at baseline. Investigators were encouraged, but not obligated, to take a fasting blood sample from consenting patients to measure blood concentrations of total homocysteine (fasting), red cell folate, vitamin B12, and creatinine. Patients were followed up every 6 months after random allocation until completion of the trial.
The primary outcome was the composite of non-fatal stroke, non-fatal myocardial infarction, or death from any vascular causes, whichever occurred fi rst. Secondary outcomes were stroke (non-fatal or fatal); myocardial infarction (non-fatal or fatal); death from any vascular cause; death from any cause; revascularisation procedures; the composite of non-fatal stroke, non-fatal myocardial infarction, and death from any vascular cause; and revascularisation procedures of the coronary, cerebral, or peripheral circulation. All investigatorreported outcomes and adverse events were audited by a masked adjudication committee.
Statistical analysis
Our sample size calculations were based on equally sized intervention and placebo groups, a minimum follow-up of 6 months for the last patient to be randomly allocated, an annual primary outcome event rate of 8% in the placebo group, 30 and a 15% decrease in the relative risk of the primary outcome among patients assigned to B vitamins (ie, 6·8% per year) compared with placebo. For a type 1 error of 5% and type 2 error of 20%, and assuming a mean follow-up of 2 years, a sample size of 3982 patients was required in each treatment group.
When recruitment began in November, 1998, we planned to complete the trial by the end of 2004. 23 Patients were therefore asked to consent to 5 years of follow-up. In 2004, when the initial patients had completed 5 years of followup, 4000 of the target of 7964 patients had been enrolled, and the primary outcome event rate in the trial population was 5·1% rather than 6·8-8%. While still masked to the event rates in each treatment group, the steering committee decided to increase the sample size and extend the duration of follow-up until at least 26 000 patient-years of follow-up had been achieved in the whole trial population. Patients were therefore asked to consent to ongoing follow-up beyond 5 years until the trial ended.
All data analyses were done according to a preestablished analysis plan. 23, 24 Baseline characteristics and laboratory data were tabulated according to the assigned treatment groups, and were expressed as proportions for categorical variables and as means (SD) for continuous variables with a normal distribution.
All patients randomly allocated to a group were included in the primary analysis. 31 We used Kaplan-Meier methods to construct cumulative time-to-event curves for the two groups, with a comparison by use of the log-rank test. 32 We used a Cox proportional hazard model analysis to control for any potential imbalance in baseline characteristics and follow-up between the two groups. 33 We also used a random eff ects model (frailty model) to investigate the possible infl uence of any variation in treatment eff ect among the various centres. In prespecifi ed subgroup analyses we compared the primary outcome between the placebo group and the B vitamins group according to age, sex, ethnic group, clinical stroke syndrome, stroke pathology, stroke cause, stroke severity, baseline blood creatinine, total homocysteine, and vitamin B12 status. 24 We also did a prespecifi ed secondary on-treatment analysis that excluded any patients who did not take any of the trial drugs or who did not comply with the protocol. We used two-sided signifi cance tests throughout and p 0·05 was deemed signifi cant.
This trial is registered with ClinicalTrials.gov, NCT00097669, and Current Controlled Trials, ISRCTN74743444.
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, the writing of the report, or in the decision to submit the paper for publication. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Between Nov 19, 1998, and Dec 31, 2008 , 8164 patients were randomly assigned to receive B vitamins (n=4089) or placebo (n=4075; fi gure 1). Demographics and baseline characteristics were similar between groups (table 1). 42% of patients were white, 24% east or southeast Asian, and 26% south Asian. The qualifying diagnosis was ischaemic stroke in 71% of patients, transient ischaemic attack in 17%, and intracerebral haemorrhage in 9%. 76% of patients were functionally independent (Oxford handicap score ≤2) at the time of random allocation. 34 Patients were followed up until June 30, 2009, with 14 182 person-years of follow-up in the B vitamins group and 13 997 person-years of follow-up in the placebo group. The median duration of follow-up was 3·4 years (IQR 2·0-5·5). 7462 (91%) of 8164 patients were followed up until the trial ended; 702 patients (9%) were lost to follow-up, primarily at three sites (n=392; 56%). The rate of loss to fi nal follow-up was 8·7% in the placebo group and 8·5% in the B vitamins group (webappendix p 1). 1543 (38%) of 4079 patients who were randomly assigned before June 30, 2004 , who had consented to 5 years of follow-up, and who were invited to continue follow-up beyond 5 years chose to stop the study drug and withdrew consent for further follow-up.
The rate of discontinuation of trial drugs increased with time, and at the same rate in each treatment group (p=0·51). In the fi rst year, 414 (10%) of 4075 patients assigned placebo and 436 (11%) of 4089 assigned B vitamins had discontinued, and at the end of the trial 1115 (27%) of 4075 patients in the placebo group and 1148 (28%) of 4089 in the B vitamins group had discontinued (webappendix p 1).
The composite primary endpoint of non-fatal stroke, non-fatal myocardial infarction, or vascular death occurred in 616 (15%) Data are number (%). Only the fi rst event was used for each type of event. One patient could have multiple diff erent types of event, so the sum of myocardial infarction, stroke, and death could be more than the total of the primary outcome. *Log-rank test. See Online for webappendix in the placebo group (4·8% per year; RR 0·91, 95% CI 0·82 to 1·00; p=0·05; absolute risk reduction 1·56%, 95% CI -0·01 to 3·16; table 2; fi gure 2). A Cox proportional hazard model analysis revealed similar hazard ratios to the RR, both before (0·90, 95% CI 0·81 to 1·00) and after (0·91, 0·81 to 1·03) adjusting for any potential imbalance in the baseline characteristics and follow-up duration between the two groups. In a random eff ects (frailty) model that was fi tted to take into account any variation in treatment eff ect between centres, the fi xed treatment eff ect (hazard ratio 0·90, 95% CI 0·81 to 1·00) was consistent with that derived from the Cox model.
Compared with placebo, treatment with B vitamins was not associated with a signifi cant reduction in the RR for non-fatal or fatal stroke (p=0·25), non-fatal or fatal myocardial infarction (p=0·86), or death from any cause (p=0·49) but was associated with a signifi cant reduction in death from vascular causes (p=0·04; table 2). For the prespecifi ed subgroups, there was no inconsistency or signifi cant interaction with the overall treatment eff ect of B vitamins (fi gure 3).
Among 1164 patients who had a fasting blood test at the end of follow-up, the mean total homocysteine concentration was 10·5 μmol/L (SD 4·9) in the Singapore (344; 30%) , and Austria (157; 13%). The eff ect of B vitamins on total homocysteine was similar in patients from these countries and those from other countries (data not shown). 925 patients had a fasting blood test for total homocysteine at both baseline and follow-up. Total homocysteine decreased by a mean of 1·09 (SD 5·5) μmol/L between baseline and follow-up, and 198 patients reached the primary endpoint. Cox regression analysis revealed that for every 1·0 μmol/L decrease in total homocysteine, the risk of the primary outcome decreased by 2·0% (95% CI -0·5 to 4·3; hazard ratio 0·98, 95% CI 0·96 to 1·01; p=0·11).
In a post-hoc secondary exploratory analysis that excluded the three sites from which 56% of the patients were lost to follow-up, the unadjusted relative risk of the primary outcome for the remaining 6789 patients was 0·91 (95% CI 0·81-1·01; p=0·073) and the adjusted RR was 0·91 (95% CI 0·80-1·03; p=0·14), which was consistent with that for the whole trial population. The results of the on-treatment analysis-which excluded 351 patients because of a protocol violation or because the patient did not take any of the trial drugs-were also consistent with the results from the whole trial population (webappendix p 2).
Vitamin B12 defi ciency was diagnosed during followup in none of the 4089 patients in the B vitamins group compared with six (0·1%) of 4075 patients in the placebo group (p=0·02). Peripheral neuropathy suspected to be caused by vitamin B6 toxicity was diagnosed in fi ve patients assigned to B vitamins (0·1%) compared with nine patients assigned to placebo (0·2%; p=0·30). There were no unexpected serious and non-serious adverse events and there were no signifi cant diff erences in common adverse eff ects between the treatment groups (data not shown).
Discussion
In the VITATOPS trial, daily treatment with the combination of folic acid, vitamin B6, and vitamin B12 after a recent stroke or transient ischaemic attack was safe but was not signifi cantly more eff ective than placebo in reducing the incidence of major vascular events. Our results are generalisable because we included a large number of patients from various ethnic groups from around the world who were not exposed to mandatory background fortifi cation of food with folic acid.
On the basis of an interpretation of the epidemiological evidence available when we designed the study, 2, 5, 23, 24 we hypothesised that daily supplementation with B vitamins would reduce total homocysteine by a quarter to a third (eg, by 3-4 μmol/L, from about 12 μmol/L to 8-9 μmol/L) and reduce the relative risk of the composite endpoint of stroke, myocardial infarction, or vascular death by 15%. Figure 4 : Eff ects of treatment with B vitamins on the composite of non-fatal stroke, non-fatal myocardial infarction, or death due to vascular causes All trials were looking at fi rst stroke, with the exception of the VISP trial and the VITATOPS trial, which included patients with a previous stroke. M-H=Mantel-Haenszel. *Data are for major vascular events as defi ned by the composite of stroke, coronary events, vascular death, and revascularisation procedures. Estimates from meta-analyses-which were published after the design of this trial-of prospective observational studies and genotype-disease association studies suggested that lowering total homocysteine by 3 μmol/L would reduce the relative risk of stroke by about 24% (15-33%) and myocardial infarction by 16% (11-20%). 3, 4 Of the 1164 patients who volunteered to have their total homocysteine measured at fi nal follow-up, patients in the B vitamins group had a similar reduction in total homocysteine compared with placebo (3·8 μmol/L, 95% CI 3·1-4·4 μmol/L) to that suggested in our hypothesis. The homocysteine-lowering eff ect of the B vitamins was consistent among diff erent ethnic groups. 35, 36 The annual rate of primary outcomes among patients assigned to placebo was lower (4·8% per year) than expected (8·0% per year), but after prolonged recruitment and follow-up (28 179 patient-years) the number of primary outcome events (n=1294) was suffi cient for the trial to be adequately powered to identify or exclude (with 95% confi dence) a 15% reduction in relative risk of the primary outcome with B vitamins compared with placebo. However, we reported only a 9% reduction in the RR of the primary outcome with B vitamins compared with placebo. The 95% CIs suggest that B vitamins might reduce the risk of the primary outcome by as much as 18% or as little as 0% compared with placebo. Therefore, our fi ndings do not defi nitively confi rm that supplementation with B vitamins has a clinically signifi cant benefi cial eff ect on major vascular events.
B vitamins versus placebo
Results from our subgroup analysis suggest that supplementation with B vitamins might reduce the risk of stroke, myocardial infarction, or vascular death in patients with symptomatic small vessel disease of the brain causing lacunar infarction or intracerebral haemorrhage. This reduction has also been suggested by other investigators who reported that homocysteine is a risk factor for cerebral small vessel disease. 28, 29 If validated, this fi nding could explain any apparent diff erential eff ect Figure 5 : Eff ects of treatment with B vitamins on stroke All trials were looking at fi rst stroke, with the exception of the VISP trial and the VITATOPS trial, which included patients with a previous stroke. M-H=Mantel-Haenszel.
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The main limitations of our trial, which could introduce bias, were incomplete adherence to trial drugs and incomplete follow-up. The high, yet similar, rates of nonadherence in each treatment group mean that any true treatment diff erences between the two groups would have been minimised, thus biasing the results to the null. Because of the high, yet similar, rates of loss to follow-up in each treatment group, small diff erences in event rates among patients lost to follow-up could have markedly aff ected the results of the trial. If we assume an absence of treatment eff ect of B vitamins among patients who were lost to follow-up and impute identical primary outcome event rates in each treatment group for those who were lost to follow-up, the relative risk for the primary outcome event would have been 0·92 (95% CI 0·83-1·01; p=0·08). If the primary outcome event rates of those lost to follow-up were consistent with the overall trial population, the relative risk for the primary event would have been 0·90 (95% CI 0·82-0·99; p=0·04). We found no evidence of a variation in treatment eff ect among centres in the random eff ects (frailty) model. If we exclude the three centres that accounted for 56% of the loss to follow-up, the results are similar to those of the whole trial population. The results of our ontreatment analysis were also consistent with our primary analysis, but they had less statistical power.
Another potential limitation of our trial is that the median duration of adherence to treatment was 2·8 years and the median duration of follow-up was 3·4 years, which might not have been long enough to adequately identify or exclude any long-term eff ects of B vitamins.
To minimise random error, we added our data to other randomised controlled trials of homocysteine-lowering therapy in patients with or without pre-existing cardiovascular disease (fi gures 4-6). 6, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] The updated metaanalysis suggests that B vitamins are not signifi cantly more eff ective than control treatments in reducing the risk of the composite of stroke, myocardial infarction, or vascular death (0·99, CI 0·94-1·03, p=0·49; fi gure 4); stroke (RR 0·94, 95% CI 0·86-1·01; p=0·10; fi gure 5); or myocardial infarction (1·00, 0·93-1·07; p=0·97; fi gure 6).
A planned meta-analysis of individual data from all previous, and three ongoing, randomised controlled trials of B vitamins will provide more reliable estimates of the long-term eff ects of B vitamins in the prevention of stroke and other major vascular events among patients with stroke or transient ischaemic attack, particularly when caused by symptomatic cerebral small vessel disease (deep intracerebral haemorrhage and lacunar infarction). [37] [38] [39] [40] Contributors GJH and JWE designed the study and directed the trial. GJH obtained funding in Australia, recruited and followed up patients, and wrote the fi rst and fi nal drafts of the manuscript. CC obtained funding in Singapore, recruited and followed up patients and was the national coordinator of the trial in Singapore. JWE obtained funding in Australia. KRL obtained funding in the UK, recruited and followed up patients, and was the national coordinator of the trial in the UK. CC, JWE, and KRL contributed to each draft of the manuscript. QY did the statistical analyses. 
VITATOPS trial study group
Research in context
Systematic review
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) on the Cochrane Library (issue 1, 2010), Medline (1950 Medline ( -2010 , Embase (1988 Embase ( -2010 , ISI Web of Science (1993 Science ( -2010 , and the Cochrane Stroke Group Specialised Register (2010). We also hand-searched relevant journals and the reference lists of included papers. We included randomised clinical trials assessing the eff ects of B vitamins (folic acid, vitamin B12, and vitamin B6) in lowering blood concentrations of homocysteine and preventing stroke and other major cardiovascular events. We assessed papers with stroke, myocardial infarction, and death attributable to vascular causes as the primary outcomes.
Interpretation
The VITATOPS trial shows, for the fi rst time, that B vitamins are safe but not signifi cantly more eff ective than placebo in reducing the risk of major vascular events among patients with a history of recent stroke or transient ischaemic attack. These results are consistent with trials of B vitamins in other patient populations.
